DANIEL LYNCH
CIK 1177082 · Chairman · last filed 2025-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
9
Total Filings
76
Lifetime Open-Market Net
-$26.43M
Filer Profile
Related Filers
bluebird bio, Inc. — 29 joint filings, latest 2021-11-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | Director | 0 | $46.99 | $0 | -$12.42M | 11 | 2025-07-02 |
| 2seventy bio, Inc. (TSVT) Delisted | Director | 21,053 | $5.00 | $105.3K | $0 | 3 | 2023-06-15 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 398 | $4.97 | $2.0K | -$8.17M | 27 | 2021-11-17 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 127,904 | $129.46 | $16.56M | -$5.84M | 18 | 2020-06-26 |
| Translate Bio, Inc. (TBIO) Delisted | Director | — | $0.00 | — | $0 | 2 | 2020-06-17 |
| Surface Oncology, Inc. (SURF) Delisted | Director | — | $1.07 | — | $0 | 2 | 2020-06-12 |
| Carisma Therapeutics Inc. (SESN) Delisted | Director | — | $12.58 | — | $0 | 2 | 2019-06-21 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | 161,430 | — | — | $0 | 4 | 2017-05-23 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | — | — | — | $0 | 4 | 2016-06-22 |
Recent Filings · Page 3 of 8
76 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-12 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-22 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-07 | Blueprint Medicines Corp (BPMC) Delisted | Gift (G) | −50,000 | $0 | EDGAR |
| 2019-09-16 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-21 | Carisma Therapeutics Inc. (SESN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-20 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-19 | Translate Bio, Inc. (TBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-10 | bluebird bio, Inc. (BLUE) Delisted | Grant (A) | +1,400 | $0 | EDGAR |
| 2019-06-06 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-25 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.